U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07366112) titled 'CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment' on Jan. 18.
Brief Summary: Exploring the dynamics of ctDNA following neoadjuvant therapy with CDK4/6 inhibitors combined with endocrine treatment, and its potential to guide de-escalation of adjuvant chemotherapy
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Hormone Receptor-Positive Breast Cancer
High-risk Breast Cancer
Early-Stage Breast Cancer
HER2-negative Breast Cancer
ctDNA Monitoring
Intervention:
DRUG: CDK4/6 inhibitor with endocrine therapy
CDK4/6 inhibitor with endocrine therapy for neoadjuvent therapy
Recruitment Status:...